

CONSOLIDATED				STANDALONE	
Quarter Ended on 31 st March 2011	Year Ended on 31 st March 2011		Particulars	Quarter Ended on 31 st March 2011	Year Ended on 31 st March 2011
(Audited)	(Audited)			(Audited)	(Audited)
18956	78805	1	(a) Net Sales / Income from Operations	18956	78805
10817	41859		Domestic	10817	38147
29773	120664		Exports	29773	116952
126	766		Total	126	766
29647	119898		Less : Excise Duty	29647	116186
85	306		Net Sales / Income from Operations	85	306
			(b) Other Operating Income		
29732	120204		Total Income	29732	116492
1613	-472	2	Expenditure	1613	-472
10793	43494		(a) Decrease/(increase) in stock in trade and work in progress	10793	43494
2594	16018		(b) Consumption of Raw Materials & Packing Materials	2594	12857
4105	14149		(c) Purchase of traded goods	4105	14149
1574	4714		(d) Employees' Cost	1574	4714
129	664		(e) Research and Development Expense	129	664
6204	25612		(f) Excise Duty	6204	25513
27012	104179		(g) Other Expenditure	27012	100919
2720	16025	3	Total	27117	100919
3	8	4	Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	2615	15573
2723	16033	5	Other Income	3	8
784	2959	6	Profit/(Loss) before Interest, Depreciation, & Exceptional Items	2618	15581
636	2389	7	Depreciation	784	2959
1303	10685	8	Interest (Net)	636	2389
0	0	9	Profit/(Loss) after Interest but before Exceptional Items	1198	10233
1303	10685	10	Exceptional Items	0	0
51	1864	11	Net Profit / (Loss) from Ordinary Activities before Tax	1198	10233
224	282		Tax Expense	23	1801
1028	8539		Less : Provision for Current Tax	224	282
3770	3770		Less/(Add) : Provision for Deferred Tax Liability/(Assets)	1028	8150
-	25758	12	Net Profit / (Loss) from Ordinary Activities after Tax	951	8150
-	2333	13	Paid up Equity Share Capital	3770	3770
0.55	4.53		(Face value of share Rs 2/-)	-	23851
-	0.86	14	Reserves excluding Revaluation Reserve	-	2333
-	2.76	15	Debt Service Coverage Ratio	-	0.81
-	9.96	16	Debt Equity Ratio	-	2.68
48,763,089	48,763,089	17	Interest Service Coverage Ratio	-	9.66
25.87	25.87	18	Public Shareholding	48,763,089	48,763,089
-	-	19	- Number of Shares	25.87	25.87
-	-	20	- Percentage of Shareholding	-	-
139,752,825	139,752,825	21	Promoters and Promoter Group Shareholding	-	-
100.00	100.00		(a) Pledged / Encumbered	-	-
74.13	74.13		Number of Shares	-	-
			Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	-	-
			Percentage of Shares (as a % of the total share capital of the Company)	-	-
			(b) Non - Encumbered	139,752,825	139,752,825
			Number of Shares	100.00	100.00
			Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	74.13	74.13
			Percentage of Shares (as a % of the total share capital of the Company)		



Notes :

- 1 The above results, which includes audited results of the Subsidiary, have been duly audited by Statutory Auditors were recommended by the Audit Committee and were approved by Board of Directors.
- 2 The Board has recommended dividend on Equity Shares at Rs. 1.00 per share i.e. 50% on 18,85,15,914 Equity Shares of Rs. 2/- each for the year ended on 31.03.2011.
- 3 The Pharmaceutical Undertaking of Alembic Limited has been demerged and transferred to the Company w.e.f. appointed date 1st April 2010 in pursuance of scheme of arrangement approved by Honorable Gujarat High Court. These financial numbers reflect the performance of Pharmaceutical Undertaking, now part of Alembic Pharmaceuticals Limited.

These financial statements have been extracted from the books of accounts maintained by Alembic Limited. This extraction and compilation is as envisaged in the scheme and based on actual data in SAP profit centres and rational allocation wherever necessary and required.


Since this is the first year of Company's operation, the previous year's figures have not been given.

- 4 The Company has allotted 13,35,15,914 equity shares of Rs.2/- each totalling Rs. 26.70 Crores to the shareholders of Alembic Limited on 15/4/2011 as per the Scheme of Arrangement approved by Honorable Gujarat High Court. These financial numbers reflect the performance of Pharmaceutical Undertaking, now part of Alembic Pharmaceuticals Limited.
- 5 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17).
- 6 The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the listing Agreement. The Standalone Financial Results are available on the company's website viz www.alembic-india.com and on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com).
- 7 Details of Investor's Complaints for the quarter ended on 31st March, 2011 : Unresolved at the beginning of the quarter-NIL
Received during the quarter-NIL, Disposed off during the quarter-NIL, Unresolved at the end of the quarter - Nil

Place : Vadodara
Date : 2nd May, 2011

Visit us at www.alembic-india.com

For Alembic Pharmaceuticals Limited



Chirayu Amin
Chairman and Managing Director

